Leishmania-derived antigens

Leishmania-derived antigens are a heterogeneous group of proteins and molecules derived from Leishmania parasites, such as Leishmania major and Leishmania donovani, which serve as targets for the host immune system (Source: PubMed, PMID: 22435874). These antigens, including well-characterized proteins like gp63 (Source: UniProt, P08105), LACK (Source: UniProt, P46290), and KMP-11 (Source: UniProt, P0C0Y4), are processed and presented by antigen-presenting cells (APCs) like dendritic cells via MHC molecules. This presentation is essential for the induction of protective Th1-type cellular immune responses, primarily involving the production of interferon-gamma (IFN-γ) by CD4+ T-cells (Source: PubMed, PMID: 19126564). In therapeutic development, these antigens are often combined into recombinant fusion proteins, such as Leish-F1, Leish-F2, or Leish-F3, to create multi-component vaccines (Source: ClinicalTrials.gov, NCT00121615). These vaccines aim to provide broad protection against various forms of leishmaniasis, including visceral and cutaneous types, by mimicking the natural presentation of parasite antigens to the immune system. Despite their potential, challenges remain regarding the durability of the immune response and the need for effective adjuvants to ensure a sustained Th1 profile (Source: PubMed, PMID: 26903205).

Other names

Leishmanial antigensLeishmania lysateRecombinant Leishmania proteinsLeishmania major antigensLeishmania infantum antigensLeishmania donovani antigens

Induction of T-cell mediated immunity through MHC-restricted antigen presentation by antigen-presenting cells.